NeOnc Technologies (NTHI) announced the completion of full patient enrollment in its ongoing NEO100-1 Phase 2a clinical trial. The trial is evaluating the company’s lead therapeutic candidate, NEO100, for the treatment of recurrent isocitrate dehydrogenase 1-mutant high-grade glioma. The Company anticipates reporting preliminary data from this fully enrolled cohort in approximately six months, during the second quarter of 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTHI:
- NeOnc Technologies Reports Promising Clinical Trial Results
- NeOnc announces updated results Phase 1/2a, compassionate care studies
- NeOnc Technologies Schedules Investor Call for Trial Updates
- NeOnc Technologies Appoints Amir Heshmatpour as New CEO
- NeOnc Technologies appoints Heshmatpour as Chief Executive Officer